CHESTER, N.J., June 8 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT - News) reports today that the Food and Drug Administration (FDA) announced that it has finalized its draft policy regarding drugs marketed in the United States that do not have required FDA approval.
